Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Use of osteoarthritis drug is suspended in UK: The UK Medicines and Healthcare Products Regulatory Agency has suspended sales of the osteoarthritis drug lumiracoxib (Prexige), pending a Europe-wide review next month. The latest global safety data have shown an increase in the risk of serious liver problems with the licensed dose of 100 mg—in some cases after treatment of less than a month. Around 5000 UK patients have received the drug since it became available in 2005, and 8.5 million prescriptions have been …

Access to the full text of this article requires a subscription or payment

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL